Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Natalie J. Sanderson"'
Autor:
Shveta Grover, Natalie J. Sanderson, James Mann, Timothy G. Ingallinera, Alexander Blanazs, Xavier Pepin
Publikováno v:
European Journal of Pharmaceutics and Biopharmaceutics. 142:421-434
Drug product dissolution for four batches of acalabrutinib 100 mg capsules were analyzed with in vitro dissolution in various pH conditions and in media containing synthetic surfactant micelles or biorelevant micelles. Non-sink conditions, where the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6dcc83255ef77b2c097cc9e9b937e2a
https://doi.org/10.1016/j.ejpb.2019.07.014
https://doi.org/10.1016/j.ejpb.2019.07.014
Autor:
Clive G. Wilson, Camille Barragat, Kelly Etherson, Toshiko Izumi, Claire Dunn, Gavin Halbert, James Butler, Wayne Matthews, Mark McAllister, Henrik Pamelund, Claudia da Costa Mathews, James Mann, Natalie J. Sanderson, Jesper Østergaard, Ibrahim Khadra
Publikováno v:
Etherson, K, Dunn, C, Matthews, W, Pamelund, H, Barragat, C, Sanderson, N, Izumi, T, Mathews, C D C, Halbert, G, Wilson, C, McAllister, M, Mann, J, Ostergaard, J, Butler, J & Khadra, I 2020, ' An interlaboratory investigation of intrinsic dissolution rate determination using surface dissolution ', European Journal of Pharmaceutics and Biopharmaceutics, vol. 150, pp. 24-32 . https://doi.org/10.1016/j.ejpb.2020.02.005
The purpose of this study was to conduct an interlaboratory ring-study, with six partners (academic and industrial), investigating the measurement of intrinsic dissolution rate (IDR) using surface d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2cee0d4ddff5f6a8a2e069314eb58ab
https://pubmed.ncbi.nlm.nih.gov/32061919
https://pubmed.ncbi.nlm.nih.gov/32061919
Autor:
Natalie J. Sanderson, Dean S. Murphy, Marilee Andrew, Timothy G. Ingallinera, George R. Bailey, Elizabeth Meehan, Andrea Moir, Xavier Pepin, Richard Barker, Cecile M. Krejsa, Allan P. Plumb, James Mann, J. Greg Slatter
Publikováno v:
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 142
Acalabrutinib (Calquence®) 100 mg (bid) has received accelerated approval by FDA for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Acalabrutinib is a substrate of PgP and CYP3A4, with a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d386f3b4419fc88cfe042b7d63da701d
https://pubmed.ncbi.nlm.nih.gov/31306750
https://pubmed.ncbi.nlm.nih.gov/31306750